Email: Cancellation terms: Cancellations must be made in writing at least 28 days before the conference date to receive a full refund. Cancellations received between 14-28 days carry a 50% cancellation fee. Special Dietary Requirements: Cancellations received less than 14 days before the event date are not eligible for a refund, but a substitute delegate is welcome. Visiongain

1. 3rd Annual Vaccine
Manufacturing
Identifying strategies for better manufacturing and development
27th – 28th October 2011, Thistle City Barbican, London, UK BOOK NOW!
Key Speakers
Abbas Rashidbaigi, Director, Pfizer
Olivier Brass, Scientist, Sanofi Pasteur
Simon Hsu, Associate Director, MedImmune
Clare Blue, Principal Virologist, Intercell Biomedical
Elizabeth Pollitt, Quality Assessor, Medicines and Healthcare products Regulatory Agency (MHRA)
Farzin Farzaneh, Professor of Molecular Medicine, King’s College London
Herman van Herk, Scientist Up Stream Process Development, Crucell
Ruth Harvey, Scientist, the National Institute for Biological Standards and Control (NIBSC)
Dennis Christensen, Head of Section Vaccine Delivery and Formulation, STATENS SERUM INSTITUT (SSI)
Alistair Noble, Senior Lecturer, King’s College London
Nigel Allison, Process Development Specialist, Health Protection Agency
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/vaccinemanufacturing

2. Conference Introduction
3rd Annual Vaccine Manufacturing
27th - 28th October 2011, London, UK
Dear Colleague, Media Partners:
he global vaccine market will achieve sustained growth over the next 15 years,
T PharmiWeb.com is the leading industry-sponsored portal
and this trend is likely to continue as governments recognise the importance for the pharmaceutical sector. Supported by most of
of mass vaccination (Source: Visiongain Report ‘Global Vaccines Market, 2010- the leading pharmaceutical corporations, PharmiWeb.com provides dynamic
2025’ published: March 2010) real-time news, features, events listings and international jobs to industry
professionals across Europe and the US.
he growth in the vaccine market as well as recent outbreaks in avian and
T For further information please email: corporate@pharmiweb.com
swine flu has highlighted the need for innovation in the manufacturing and
development of vaccines to bring greater efficiencies.
isiongain’s 3rd Annual Vaccine Manufacturing conference will feature key
V BIOTECHNOLOGY EUROPE is owned by
industry experts, who will assess the current landscape of vaccine development BIOTECHNOLOGY WORLD. It is based and located in
and address challenges face by manufactures. The attendees will hear the latest Warsaw, Poland. Biotechnology World was founded in 2007 to provide the
innovative strategies and technologies. Join us and be inspired. world’s biotech and pharma information and market to make it universally
accessible and useful for scientific and business processes. Its first step
Why you should attend this conference to fulfilling that mission was building the BIOTECHNOLOGY EUROPE
• Identify innovative vaccine developments and manufacturing strategies platform that will allow a quick spread of information in different channels.
BIOTECHNOLOGY EUROPE offers companies completed internet public
• Review important regulatory requirements relations, publication and marketing solutions. One of the mains goals of
• Assess immunological challenges BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in
Europe to global biotechnology, pharmaceutical and life science activities.
• Understand strategies for improving influenza vaccine strains For further information please visit: www.biotechnology-europe.com
• Explore opportunities in emerging markets
• Use this platform to forge future business collaborations Future Pharmaceuticals has forged powerful
Driving the Industry Forward | www.futurepharmaus.com
relationships with key industry leaders to provide a
I look forward to meeting you at the conference
platform for successful brand recognition, and for senior decision-makers to
Best regards have the means to procure and plan implementation strategies based on the
topics covered. Positioned to be an authoritative resource within top pharma
companies as well as small, specialty, and biotech, Future Pharmaceuticals
magazine is geared to create a deep penetration into a highly targeted and
responsive audience, bridging the gap between the industries’ top issues and
Koos Mohammed the solutions top-tier vendors can provide.
Conference Producer For further information please visit: www.futurepharmaus.com
InPharm is the online platform for exclusive
pharmaceutical news, comment, contracts, services, jobs
and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus.
Who should attend this conference?
For further information please visit: www.inpharm.com
VPs, Directors, Heads, Managers working within:
Vaccine equipment and manufacturing
Vaccine application development
Vaccinology and molecular biology
Sponsorship and exhibition opportunities
Proteomics, recombinant protein/DNA biotechnology
Infectious disease R&D This event offers a unique opportunity to meet and do business with some
Pharmacovigilance and safety testing of the key players in the pharmaceutical and biotech industries. If you have
Regulatory affairs a service or product to promote, you can do so at this event by:
Strategic product development
• Hosting a networking drinks reception
Manufacturing/production
• Taking an exhibition space at the conference
Chemistry manufacturing and controls
Process control and Analytical Technologies • Advertising in the delegate documentation pack
Clinical product resourcing • Providing branded bags, pens, gifts, etc.
Supply outsourcing project management
If you would like more information on the range of sponsorship or
Contract management
exhibition possibilities for visiongain's 3rd Annual Vaccine Manufacturing
Process development
Drug discovery & deliver
Conference, please contact us:
Legal Affairs Damian Gorman, +44 (0)20 7549 9934
Investment and venture capital damian.gorman@visiongainglobal.com

3. Day 1
3rd Annual Vaccine Manufacturing
Thursday 27th October 2011
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the chair 13:40 Novel technologies for improving the scale of
production of influenza vaccine
09:40 Regulatory requirements for vaccines: quality aspects • Speeding up the production process
• uality requirements for marketing authorisation of a new vaccine
Q • Fewer contamination
• ost licensing issues arising from manufacturing changes
P Herman van Herk
Scientist Up Stream Process Development
• istorical examples to high light problems
H
Crucell
• uccessful strategies to implement manufacturing changes
S
Elizabeth Pollitt
Quality Assessor 14:20 Abrogating CD8 T cell tolerance with
MHRA multifactorial adjuvants
• Nature of CD8 T cell tolerance
10:20 The redevelopment of licensed vaccines • Pathways leading to clonal expansion of Ag-specific CD8 T cells
• Why redevelop a mature process? • omponents of multifactorial adjuvants required for CTL responses
C
and tumour rejection
• The regulatory challenges
Alistair Noble
• Process redevelopment Senior Lecturer
• Application of improved analytical methods King’s College London
• Anthrax vaccine: A case study
Nigel Allison 15:00 Afternoon Refreshments
Process Development Specialist
Health Protection Agency
15:20 Increasing access to pandemic influenza vaccines
11:00 Morning refreshments • Sustaining appropriate manufacturing capacity
• Enhancing vaccine performance
11:20 Tailoring adjuvants for future vaccines • Process improvements
• Challenges in vaccinology Simon Hsu
Associate Director
• Accessible vs. ideal adjuvants MedImmune
• Administration route and immunity
Dennis Christensen
Head of Section, Vaccine Delivery and Formulation
16:00 The case for cell-based manufacturing methods
Statens Serum Institut • Faster vaccine production
• Ideal in times of pandemic
12:00 New trends in early vaccine stability assessment • Reduced allergic reactions
and stabilization strategies
• ase studies: stability and stabilization of protein, adjuvanted
C
glycoprotein, and live attenuated virus 16:40 Closing remarks from the chair
• ational approaches for an early vaccine stability and
R
immunogenicity assessment
• Stabilization strategy for early and late product stage
16:50 Networking drinks
Olivier Brass
Scientist Take your discussions further and build new
Sanofi Pasteur relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

4. Day 2
3rd Annual Vaccine Manufacturing
Friday 28th October 2011
09:00 Registration and refreshments 13:40 Ensuring vaccine safety: Challenges posed by
adventitious viral agents
• Current testing requirements
09:30 Opening address from the chair
• Techniques available
• Problems associated with adventitious agent testing
09:40 Cell, gene and peptide based vaccines for • Positive result: What does this mean?
therapeutic applications in cancer • Future perspective
• Immune mediated rejection of established tumours
Clare Blue
• afety and potential efficacy of hTERT peptide loaded dendritic
S Principal Virologist
cell vaccination Intercell Biomedical
• ew vaccination strategy based on the combined adjuvants for
N
synergistic activation of cellular immunity (CASAC)
14:20 Improving influenza vaccine strains
Farzin Farzaneh
Professor of Molecular Medicine • Generation of candidate vaccine viruses
King’s College London
• Genetic engineering of vaccine strains
• Improved antigen yield from new candidate vaccine viruses
10:20 Thimerosal in Vaccines: Is it an Ruth Harvey
effective preservative? Scientist
National Institute for Biological
• ompendial methods for determination of preservative effectiveness
C Standards and Control (NIBSC)
• HO requirements
W
• reservatives for multi-dose formulations
P
15:00 Afternoon refreshments
• election of a preservative for Prev(e)nar 13™ vaccine
S
• low rate of Thimerosal effectiveness
S
Abbas Rashidbaigi 15:20 Modern development of a novel recombinant
Director tuberculosis vaccine VPM1002
Pfizer
• Prime TB vaccine
• Effective VPM1002 fermentation
11:00 Morning refreshments • Long-lasting IMP
• Live recombinant vaccine
Leander Grode
Director Business Development
11:20 Sponsor Spotlight Session Vakzine Projekt Management GmbH
T
ake this unique opportunity to be a part of the conference theme,
network, share ideas and provide an overview of your product/services
to the audience. For more information please contact
16:00 Emerging vaccine markets
damian.gorman@visiongainglobal.com
• Strengths and weaknesses
• Challenges and opportunities
12:00 Outsourcing vaccine production
• Developing an outsourcing strategy 16:40 Chair’s closing remarks
• Accessing appropriate equipment
• Coping with the demand during pandemics 16:50 End of Conference
12:40 Networking lunch

5. Registration Form
3rd Annual Vaccine Manufacturing
27th - 28th October 2011, London, UK
Conf. code PP
3rd Annual Vaccine
Standard Prices
Manufacturing
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 27th - 28th October 2011
Location: Thistle City Barbican
Number of bookings: Total cost:
Address:
Central Street, Clerkenwell
Promotional Literature Distribution London
Distribution of your company’s promotional literature to all conference attendees EC1V 8DS
Fee: £999 VAT: £199.80 Total: £1198.80
Details How to book
Email: piyush.patel@visiongain.com
Forename: Surname: Web: http://www.visiongain.com/vaccinemanufacturing
UK Office:
Job Title: Company:
Tel: +44(0) 20 7549 9961
Fax: +44(0) 20 7549 9932
Main Switchboard Number: Visiongain Ltd
230 City Road
Address: London
EC1V 2QY
UK
General information
Country: Postcode: Venue: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 9004 /
+44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343
http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Phone: Fax:
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
Email: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
Signature: Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
I confirm that I have read and agree to the terms and conditions of booking after one month before the start of the event. Should you decide to cancel after this date, the full invoice
must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
between conferences. However, if you cannot attend the conference, you may make a substitution/name
Methods of payment change at any time, as long as we are informed in writing by email, fax or post. Name changes and
Payment must be made in sterling substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
By Mail: Complete and return your signed registration form together with your cheque payable Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Fax: Complete and fax your signed registration form with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
By Bank Transfer:
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Visiongain Ltd A/C: visiongain Ltd Protection Act 1988. Your personal information contained in this form may be used to update you on
Barclays Bank Sort Code: 20-71-64 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please
48 Regent Street Swift Code: BARC GB22
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database.
Please debit my credit card: Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Expiry Date: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Security number (last 3 digits on back of credit card): Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
Signature: with your payment. You will receive speaker talks in PDFs two weeks after the event.
Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
Cardholder’s name:
Office use only
News updates
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/vaccinemanufacturing